Newsroom
Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Corporate Sustainability
  • Careers
Company Announcement
10 February 2023

Settlement of Alvotech Private Share Placement Completed

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the completion of the equity...
Company Announcement
09 February 2023

EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) EMA opinion on AVT04 could come as soon as the...
Company Announcement
06 February 2023

Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab)

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand Alvotech (NASDAQ: ALVO), a...
Company Announcement
24 January 2023

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

AVT02 as Simlandi™ is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of GlobalOne...
Inside information
23 January 2023

Alvotech Completes $137 Million Private Share Placement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement...
Inside information
20 January 2023

Alvotech initiates proposed private share placement to professional clients and eligible counterparties in Iceland

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today confirmed the initiation of a proposed private placement of ordinary shares, made in an overseas directed offering, directed solely into Iceland to
Company Announcement
17 January 2023

FDA Inspection of Manufacturing Facility

On January 17, 2023, Alvotech received written confirmation via email from the U.S. Food and Drug Administration (FDA) that the reinspection of its facility in Reykjavik, Iceland is scheduled for March 6, 2023. As previously communicated on December 22, 2022, the FDA has granted a new Biosimilar Use
Company Announcement
13 January 2023

Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Japanese pharmaceutical company Fuji Pharma Co.,...
Company Announcement
11 January 2023

Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic...
Company Announcement
06 January 2023

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory...
1…2223…32
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.